TABLE 2.

Adhesion of S. aureus strain FDA486 and corresponding rsbU, rsbV, and rsbW mutants to immobilized fibrinogen and fibronectin in the presence or absence of SAL

Strain or mutant	Fibrinogen binding			Fibronectin binding
	Controla	SAL (%)b		Controla	SAL (%)b
		25 μg/ml	50 μg/ml		25 μg/ml	50 μg/ml
FDA486	4.2 ± 1.1	−25.40	−47.10c	3.8 ± 1.1	−20.90	−45.50c
rsbU mutant	4.5 ± 1.2	−14.20	−23.30	4.8 ± 1.3	−15.40	−24.30
rsbV mutant	4.5 ± 1.1	−8.90	−22.10	4.8 ± 1.0	−13.90	−25.30
rsbW mutant	4.9 ± 0.8	−11.80	−21.10	4.5 ± 1.4	−8.30	−13.10

^aPercent binding of initial inoculum to ligand in the absence of SAL.

^bMean percent reduction in binding comparing SAL-treated versus untreated (control) S. aureus cells. These data are derived from the means of three independent runs and are expressed as mean percent reductions of fibrinogen or fibronectin binding under various assay conditions.

^cP < 0.05 versus untreated control cells.